艾伯维BCL-2抑制剂拓适应症失利,罗氏帕金森药进Ⅲ期,FXIIa单抗在美上市

医药经济报
Yesterday

1.艾伯维/基因泰克BCL-2抑制剂拓适应症暂折戟6月16日,基因泰克与艾伯维宣布,BCL-2(B细胞淋巴瘤-2)抑制剂Venclexta联合阿扎胞苷初治高危骨髓增生异常综合征(MDS)患者的Ⅲ期VERONA研究(NCT04401748)临床试验未达总生存期(OS)这一主要终点。VERONA是一项由艾伯维主导的全球Ⅲ期多中心、随机、双盲对照研究,评估Venclexta联合阿扎胞苷与安慰剂联合阿扎胞...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10